IP Library Granted Patent US 9,005,610
Granted Patent B2
US 9,005,610 · App. 13/843,369 · Granted Apr 14, 2015

Treatment of gluten intolerance and related conditions

Inventors: David Schriemer (Chestermere, CA); Petr Man (Prague, CZ); Hynek Mrazek (Prague, CZ); Martial Rey (Calgary, CA)
Assignee: Nepetx, LLC
A61K38/488A23L1/3002C12Y304/23012A23L1/034A23L1/30A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,610
App. No.
13/843,369
Granted
Apr 14, 2015
Kind
B2
Abstract

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori . Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

Claims (9)

1. A method for treating or attenuating gluten intolerance, celiac disease, wheat allergy, or dermatitis herpetiformis in a patient in need thereof, comprising administering to said patient an effective amount of nepenthesin, wherein said nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, or mixtures of said nepenthesins, such that gluten is degraded by the nepenthesin, thereby treating or attenuating gluten intolerance, celiac disease, wheat allergy, or dermatitis herpetiformis in the patient.

2. The method of claim 1 , wherein said nepenthesin is administered to the patient prior to ingestion of a food comprising gluten or suspected of comprising gluten.

3. The method of claim 1 , wherein said nepenthesin is administered to the patient with ingestion of a food comprising gluten or suspected of comprising gluten.

4. The method of claim 1 , wherein said nepenthesin is administered to the patient after ingestion of a food comprising gluten or suspected of comprising gluten.

5. The method of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 3.

6. The method of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 4.

7. The method of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 5.

8. The method of claim 1 , wherein the nepenthesin comprises the amino acid sequence of set forth in SEQ ID NO: 6.

9. The method of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 7.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: CODEXIS, INC.
Reel/Frame 069789/0740 →
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2020
From: NEPETX, LLC
To: CODEXIS, INC.
Reel/Frame 052804/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: MAN, PETER; MRAZEK, HYNEK
To: NEPETX, LLC
Reel/Frame 035190/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2014
From: SCHRIEMER, DAVID C.; REY, MARTIAL
To: NEPETX, LLC
Reel/Frame 033876/0240 →
Continuity (3)
Provisional Application 61729210 · Nov 21, 2012
Provisional Application 61797040 · Nov 27, 2012
Related Publication 20140186330A1 · Jul 3, 2014